Disclosed is an antibody that binds to proprotein convertase subtilisinlkexin type 9 (PCSK9), wherein the antibody comprises the CDRs/VH and VL chains of the sequences as defined in the specification, and wherein the antibody: a) does not block PCSK9 binding to the low density lipoprotein receptor (LDLR) and b) inhibits PCSK9-mediated degradation of LDLR.